A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...
A doctor, bariatric surgeon and professor say that treatments other than weight-loss drugs are needed to fix the obesity ...
The holidays are a time known for feasting on delicious food, but that might not be possible for people taking weight-loss drugs.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular ...
Reports of pulmonary aspiration and difficulties in diagnosing gastrointestinal complications in the perioperative period have highlighted the need for clear clinical guidance to manage these patients ...
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...
The use of GLP-1s is linked to improved inflammatory bowel disease outcomes in patients with concomitant inflammatory bowel ...
A study reveals that weight loss can lead to significant healthcare savings, with 7% savings for a 5% BMI reduction and 30% ...
There’s no single GLP-1 diet plan you need to follow. If you’re taking — or thinking about taking — a GLP-1 medication like ...
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
After this, the situation will be reviewed by Nice, who will provide further guidance on the rollout. Mounjaro is a ...
Other work primarily only included glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among individuals with substance use disorders. We also compared GLP-1 RAs to metformin and ...